MBX Biosciences Maintains "Buy" Rating with Increased Price Target

• Guggenheim maintains a "Buy" rating for NASDAQ:MBX, raising the price target from $44 to $84.

• Canvuparatide, MBX's once-weekly treatment, shows promising results in a Phase 2 trial with a 63% responder rate at 12 weeks and a 79% rate at 6 months.

• The stock price of MBX Biosciences has surged 105.05%, reflecting strong investor confidence.

MBX Biosciences, trading under the symbol NASDAQ:MBX, is a biotechnology company focused on developing innovative treatments. On September 22, 2025, Guggenheim maintained its "Buy" rating for MBX, with a "hold" action, while raising the price target from $44 to $84, as highlighted by TheFly. At that time, the stock was priced at $10.

MBX's recent success with its once-weekly treatment, Canvuparatide, has likely influenced Guggenheim's optimistic outlook. The treatment achieved a 63% responder rate at 12 weeks and a 79% rate at 6 months in a Phase 2 trial. These promising results, with no serious adverse events, suggest strong potential for future growth.

The stock has seen a significant increase, currently priced at $20.51, marking a 105.05% rise. This surge reflects investor confidence, likely driven by the positive trial outcomes. The stock has fluctuated between $20 and $26.45 today, with a 52-week high of $27.50 and a low of $4.81.

MBX's market capitalization is approximately $688.84 million, with a trading volume of 19,500,369 shares. The company's strong performance in the trial and the upcoming Phase 3 trial in 2026 are key factors contributing to its market position. Investors are closely watching MBX's progress and potential future developments.